Quantitative PCR was performed to analyze relative gene expression level of treated HeLa cells using target specific primers. Gene expression levels relative to GAPDH were normalized to control treatment. The data shown represent the mean ± SEM (n= 3, technical replicates) of one experiment. Statistical significance compared to the control was determined with two-tailed t tests: *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant. mRNA expression of BRD2, BRD3 and BRD4 were selectively suppressed upon transfection of their respective siRNA. HeLa cells were transfected with siRNA targeting individual BRD2, BRD3 or BRD4 or with negative control siRNA and were harvested after 48 hours.
Quantitative PCR was performed to analyze relative gene expression level of treated HeLa cells using target specific primers. Gene expression levels relative to GAPDH were normalized to control treatment. The data shown represent the mean ± SEM (n= 3, technical replicates) of one experiment. Statistical significance compared to the control was determined with two-tailed t tests: *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant.
Materials and Methods

Chemistry
General information NMR spectra were recorded on a Bruker 500 Ultrashield or a Bruker Ascend 400. Chemical shifts are quoted in ppm and referenced to the residual solvent signals: 1 H δ = 7.26 (CDCl 3 ), 13 C δ = 77.16 (CDCl 3 ). High Resolution Mass Spectra (HRMS) were recorded on a Bruker micrOTOF. All chemicals, unless otherwise stated were commercially available and used without further purification. Enantiopure (+)-JQ1 was purchased from Medchemexpress LLC, Princeton, USA. Flash column chromatography was performed using a Teledyne Isco Combiflash Rf or Rf200i. As prepacked columns RediSep Rf Normal Phase Disposable Columns were used. Preparative HPLC was performed on a Gilson Preparative HPLC System with a Waters X-Bridge C18 column (100 mm x 19 mm; 5 μm particle size) and a gradient of 20 % to 95 % acetonitrile in water with 0.1 % ammonia in the aqueous phase.
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Synthetic procedures
The following compounds were prepared according to literature procedures : 4 and 5, 1 PEG linkers 6 and 7. 
tert-butyl (2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate (8)
To a solution of (4-(4-methylthiazol-5-yl)phenyl)methanamine 1 (500 mg, 2.43 mmol, 1 eq.) in 
General procedure for Boc-deprotection:
The N-Boc-protected compound was dissolved in dichloromethane (10 ml/1 mmol). Trifluoroacetic acid (10 ml/1 mmol) was added and the reaction mixture stirred at room temperature for 2 h. The solvent was removed under reduced pressure. For three times dichloromethane (5 ml /1 mmol) was added and then the solvent again removed in vacuum to remove residual trifluoroacetic acid. 
General procedure for linker coupling:
The amine (10 -12) (1 mmol, 1 eq.) was added to a solution of PEG-linker (6, 7) (1.2 mmol, 1.2 eq.) in DCM (40 ml). HATU (570 mg, 1.5 mmol, 1.5 eq.) was added and the pH adjusted to >9 by addition of DIPEA (700 μl, 4 mmol, 4 eq.). After stirring for 4 h at 25 °C the reaction mixture was extracted with water. The organic phase was dried over Magnesium sulfate and evaporated to dryness. The crude product was purified by flash column chromatography using a gradient of 0%-6% of Methanol in Dichloromethane. 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4 ]diazepin-6-yl)acetic acid (17). S16 (+)-JQ1 (50 mg, 109 μmol) was dissolved in formic acid (3 ml) and stirred for 18 h at 25 °C. After addition of water the reaction mixture was extracted three times with dichloromethane. The combined organic layers were dried over magnesium sulfate and evaporated to dryness to obtain the title compound which was directly used for the next reaction step. Yield 42.1 mg (96 %).
(2S,4R)-1-((S)-14-azido-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (13
(2S,4R)-1-((2S,5S)-17-azido-5-benzyl-2-(tert-butyl)-4,7-dioxo-9,12,15-trioxa-3,6-diazaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
General procedure for PROTAC formation:
Azides 13 -16 (50 μmol) were dissolved in methanol (5 ml). Catalytic amount of palladium on Charcoal (10 wt%) was added and the reaction mixture stirred under an atmosphere of hydrogen for 3 h at 25 °C. The reaction mixture was filtered through a plug of celite and the resulting solution evaporated to dryness to obtain the desired amine.
The resulting amines (45 μmol, 1.1 eq.) and 17 (16.0 mg, 40 μmol, 1 eq.) were dissolved in DCM (2 ml). HATU (22.8 mg, 60.0 μmol, 1.5 eq.) was added and the pH adjusted to >9 by adding DIPEA (41.9 μl, 240 μmol, 4 eq.). After stirring the reaction mixture at 25 °C for 18 h the solvent n
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was removed in vacuum. Purification of the crude was achieved by preparative HPLC as described in the general information. 
(2S,4R)-1-((S)-2-(tert-butyl)-20-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,19-dioxo-6,9,12,15-tetraoxa-3,18-diazaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (MZ2
(2S,4R)-1-((2S,5S)-5-benzyl-2-(tert-butyl)-20-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,7,19-trioxo-9,12,15-trioxa-3,6,18-triazaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (MZ3
S19 (2S,4S)-1-((S)-2-(tert-butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (cisMZ1
Biophysics Protein expression and purification:
Plasmids pNIC28-Bsa4 containing the single BET bromodomain constructs BRD2 BD1, BRD2 BD2, BRD3 BD1, BRD3 BD2, BRD4 BD1 and BRD4 BD2 for protein expression are obtained from previous study. 3 Subsequent expression and purification was based on the methods in previous study with slight modifications. Single colonies from freshly transformed plasmid DNA in competent E. coli BL21(DE3) cells were grown overnight at 37 °C in 10 mL of LB medium with 50 μg/mL kanamycin. Starter culture was then diluted 1:100 in fresh Luria Broth (LB) medium with 50 μg/mL of kanamycin. Cell growth was allowed at 37 °C and 200 rpm to an optical density of about 2.5 (OD600), at which point temperature was decreased to 18°C. Once the cultures equilibrated at 18 °C, protein expression was induced overnight at 18 °C with 0.4 mM isopropyl-β-thiogalactopyranoside (IPTG). The bacteria was harvested the next day by centrifugation (8000 rpm for 10 minutes at 6 °C, JLA 8.1000 rotor on a Beckman Coulter Avanti J-20 XP centrifuge) and frozen at -20 °C as pellets for storage. Pellets of cells expressing His 6 -tagged proteins were resuspended in lysis buffer (50 mM HEPES pH 7.5 at 25 °C, 150 mM NaCl, 40 mM Imidazole and 2 mM β-mercaptoethanol). One tablet of Complete Protease Inhibitor Cocktail (Roche) was added to the resuspension and cells were lysed using a French Press at 4 °C. Following a 20 min incubation period at room temperature with 10 μg/mL DNaseI and 10 mM MgCl2, the cell debris was removed by centrifugation, 20,000 x g at 4 °C. The lysate was purified via immobilized metal ion affinity chromatography on a His Trap HP 5mL Ni sepharose column (GE Healthcare Life Sciences) on an ÄKTApure system (GE Healthcare). His 6 -tagged protein was eluted using a linear gradient to 250 mM imidazole in the same buffer. After Ni purification, the pooled elution fractions were concentrated to a volume of 4 mL and further purified by size exclusion chromatography on a Superdex 75 16/60 Hiload gel filtration column (GE Healthcare) on an ÄKTApure system using the following buffer: 20 mM HEPES pH 7.5, 150 mM NaCl. Samples were monitored by SDS-polyacrylamide gel electrophoresis to verify purity. Pure protein was then flash frozen with liquid nitrogen and stored at -80 °C. The mass and purity of the proteins were subsequently verified by mass spectrometry.
Isothermal Titration Calorimetry (ITC):
ITC experiments were carried out at an ITC 200 instrument from MicroCal TM with a concentration in the measuring cell of 15 μM and a syringe concentration of 150 μM. Experiments were conducted as PROTAC compound into protein titrations, except in the case of MZ3 where protein was titrated into PROTAC. BET protein experiments were conducted in a buffer containing 20 mM HEPES with 100 mM NaCl at pH 7.5 and a temperature of 30 °C. VBC protein experiments were carried out in a buffer containing 20 mM Bis-Tris, 150 mM NaCl and 2 mM Dithiothreitol (DTT) at pH 7 and a temperature of 25 °C. 
Biology Reagents
The proteasome inhibitor MG132 and radio immunoprecipitation assay buffer (RIPA-buffer) were purchased from Sigma Aldrich. DMEM media, phosphate buffered saline (PBS) and heat deactivated fetal bovine serum (FBS) were purchased from Gibco, Life Technologies. Complete Mini EDTA free Protease inhibitor cocktail was purchased from Roche. Lipofectamine® RNAiMAX Transfection Reagent from Life Technologies. siRNA from Life Technologies, cat. # 4390843, (E2691).
Tissue culture
HeLa and U2OS cells were cultured in DMEM supplemented with 10 % FBS, 1 % L-glutamine and 100U/ml of penicillin/streptomycin. Cells were maintained for no more than 30 passages at 37 °C and 5 % CO 2 .
Cell treatment
Small interfering RNA
For siRNA inhibition studies, cells were plated in six-well plates and were grown to 50-60% confluence. Cells were transfected with siRNA targeting BRD2, BRD3 or BRD4 or negative control siRNA at a final concentration of 12 nM in the presence of lipofectamine reagent. After transfection, cells were cultured for another 24 hours for treatment with compound or harvested after 48 hours for gene expression study.
Single time point treatment
For treatment experiments cells were transferred in 6-well plates with 500 000 cells per well in 2 ml media. 12 h after settling 200 μl of media was removed and then replaced by a 10 fold concentrated compound solution in media. The final DMSO concentration was 0.01 % v/v.
Time course experiments
For time dependent treatment cells were transferred in 6-well plates with 300 000 cells per well in 2 ml media. For treatment 200 μl of media was removed and then replaced by a 10 fold concentrated compound solution in media. Treatment was conducted at given time points prior to harvest.
Protein recovery experiment
Cells were transferred in 6-well plates with 300 000 cells per well in 2 ml media. For treatment 200 μl of media was removed and then replaced by a 10 fold concentrated compound solution in media. 4 h after treatment the media was aspirated and replaced by fresh media without treatment. Cells were harvested at given time points.
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Western blotting
For protein extracts the dishes were placed on ice. 
RNA extraction and real-time PCR
Expression levels of genes of interest were analysed by RT-PCR. After treatment described above, cells were harvested and RNA was extracted with Qiagen RNeasy Mini Kit (cat. #: 74104). Reverse transcription were performed using 250-500 ng of extracted RNA with Bio-Rad iScript cDNA synthesis Kit (cat. #: 170-8891). The cDNA samples were diluted by 25-fold. Gene-specific primers designed with aid of UCSC Genome Browser. 
GAPDH-rv GCATCAGCAGAGGGGGCAGAG
All PCR reactions were performed using the Bio-Rad CFX96 Touch Real-Time PCR system and the amplifications were done using the Quanta PerfeCTa® SYBR® Green FastMix for iQ (cat. # 95071). The thermal cycling conditions were composed of 95°C for 10 min, 45 cycles at 95°C for 10s and 60°C for 30s followed by a ramping temperature step to 95°C for melt-curve analysis. The experiments were carried out in triplicate for each data point. The data was analysed using CFX Manager software from Bio-Rad and the relative quantification in gene expression was determined by normalising to the control gene GAPDH.
Fluorescence microscopy:
U2OS cells transiently expressing GFP-tagged BRD4 were prepared. Plasmid pcDNA5/FRT/TO-GFP containing full-length wild-type BRD4 is obtained as described in previous study. 3 U2OS
cells were plated onto a glass bottom microwell dish (MatTek, P35G-1.5-14-C) in 2.5 mL medium and were grown to 50-60% confluence. Then the cells were transfected with 4 μg of plasmid DNA in the presence of FuGene 6 Transfection Reagent (Promega, E2691). Twelve hours after S27 transfection, medium was removed in exchange of fresh medium supplemented with 0.5 µg/mL tetracycline to induce GFP-BRD4 expression. After 18 hours, medium was removed again in exchange of fresh medium without tetracycline. After 6 hours, compound MZ1 or cis-MZ1 were added to the plate. Immediately after the treatment, fluorescence given out from individual cells plate were observed on a DeltaVision Elite imaging system with excitation at 480 nm and emission at 525 nm. Images of individual cells were made at regular time interval to observe changes in fluorescence over time.
Legends to Supporting Information videos:
Supporting video a: BRD4 depletion by MZ1 monitored by live fluorescence imaging.
U2OS cells transfected with GFP-BRD4 were treated with 5 μM of MZ1 over a time course of 4 hours. GFP-BRD4 degradation was followed by live fluorescence imaging using a DeltaVision Elite Imaging system. The pictures taken every 2 minutes were combined to a 10 second time lapse video.
Supporting video b: Intracellular amount of GFP-BRD4 does not change in the presence of cisMZ1.
U2OS cells transfected with GFP-BRD4 were treated with 5 μM of cisMZ1 over a time course of 4 hours. Live fluorescence imaging using a DeltaVision Elite Imaging system showed no reduction in fluorescence. The pictures taken every 2 minutes were combined to a 10 second time lapse video.
